{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:41Z","timestamp":1793821721517,"version":"4.6.1"},"reference-count":175,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines. Results: We identified 134 publications (89 retrospective), comprising 10 pharmaco-epidemiologic and 83 clinic-based studies, 38 case reports, and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest that there are reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbs. Effectiveness, reported in 77 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency, and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 86 papers, including 24 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers, and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-ups of patients treated with anti-CGRP-mAbs.<\/jats:p>","DOI":"10.3390\/cells12010143","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T03:14:28Z","timestamp":1672370068000},"page":"143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2300-674X","authenticated-orcid":false,"given":"Antun R.","family":"Pavelic","sequence":"first","affiliation":[{"name":"Department of Neurology, Hietzing Hospital, 1130 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1382-1978","authenticated-orcid":false,"given":"Christian","family":"W\u00f6ber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Riederer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hietzing Hospital, 1130 Vienna, Austria"},{"name":"Faculty of Medicine, University of Zurich, 8032 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Zebenholzer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria"},{"name":"Comprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","first-page":"22","article-title":"Systematic Review of Migraine Prophylaxis Adherence and Persistence","volume":"20","author":"Hepp","year":"2014","journal-title":"J. Manag. Care Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1177\/0333102419867282","article-title":"Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries","volume":"39","author":"Ohlsson","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1177\/0333102419863027","article-title":"Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries","volume":"39","author":"Haanes","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A Controlled Trial of Erenumab for Episodic Migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","article-title":"Fremanezumab for the Preventive Treatment of Chronic Migraine","volume":"377","author":"Silberstein","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: A randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: A randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): A randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1111\/head.13970","article-title":"Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and\/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies","volume":"60","author":"Smitherman","year":"2020","journal-title":"Headache"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1212\/WNL.0000000000007497","article-title":"Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial","volume":"92","author":"Tepper","year":"2019","journal-title":"Neurology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/0333102420966658","article-title":"Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine","volume":"41","author":"Dodick","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s10194-020-01173-8","article-title":"The impact of fremanezumab on medication overuse in patients with chronic migraine: Subgroup analysis of the HALO CM study","volume":"21","author":"Silberstein","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2","volume":"61","author":"Diener","year":"2021","journal-title":"Headache"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2250","DOI":"10.1212\/WNL.0000000000007452","article-title":"Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study","volume":"92","author":"Lipton","year":"2019","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1212\/WNL.0000000000010000","article-title":"Effect of fremanezumab on quality of life and productivity in patients with chronic migraine","volume":"95","author":"Lipton","year":"2020","journal-title":"Neurology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e508","DOI":"10.1212\/WNL.0000000000007856","article-title":"Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability","volume":"93","author":"Ford","year":"2019","journal-title":"Neurology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-022-01386-z","article-title":"Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a \u226575% response to eptinezumab: Subgroup pooled analysis of the PROMISE trials","volume":"23","author":"Lipton","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/ene.14715","article-title":"Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial","volume":"28","author":"Ashina","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Camporeale, A., Kudrow, D., Sides, R., Wang, S., Van Dycke, A., Selzler, K.J., and Stauffer, V.L. (2018). A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol., 18.","DOI":"10.1186\/s12883-018-1193-2"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kudrow, D., Cady, R.K., Allan, B., Pederson, S.M., Hirman, J., Mehta, L.R., and Schaeffler, B.A. (2021). Long-term safety and tolerability of eptinezumab in patients with chronic migraine: A 2-year, open-label, phase 3 trial. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02123-w"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40120-021-00303-x","article-title":"Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine","volume":"11","author":"Autio","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s40122-021-00319-z","article-title":"Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data","volume":"10","author":"Chandler","year":"2021","journal-title":"Pain Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/head.14218","article-title":"Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study","volume":"62","author":"Gladstone","year":"2022","journal-title":"Headache"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/head.14068","article-title":"Erenumab patient characteristics, medication adherence, and treatment patterns in the United States","volume":"61","author":"Hines","year":"2021","journal-title":"Headache"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","article-title":"Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States","volume":"22","author":"McAllister","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_37","first-page":"1157","article-title":"Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States","volume":"27","author":"Tepper","year":"2021","journal-title":"J. Manag. Care Sp\u00e9c. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-021-01238-2","article-title":"Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: A US claims database study","volume":"22","author":"Tepper","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2147\/PPA.S346660","article-title":"Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study","volume":"16","author":"Varnado","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1111\/head.13956","article-title":"Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study","volume":"60","author":"Alex","year":"2020","journal-title":"Headache"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","article-title":"Erenumab and Onabotulinumtoxin A Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis","volume":"35","author":"Armanious","year":"2021","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e2260","DOI":"10.1002\/brb3.2260","article-title":"Predictors of response to erenumab after 12 months of treatment","volume":"11","author":"Baraldi","year":"2021","journal-title":"Brain Behav."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s10194-021-01267-x","article-title":"MAB-MIG: Registry of the spanish neurological society of erenumab for migraine prevention","volume":"22","author":"Irimia","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40122-021-00264-x","article-title":"Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to Onabotulinumtoxin A: A Retrospective Chart Review","volume":"10","author":"Blumenfeld","year":"2021","journal-title":"Pain Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","article-title":"Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: An observational, retrospective, 12-month real-life study","volume":"42","author":"Cainazzo","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1093\/pm\/pnab093","article-title":"Efficacy and Tolerability of Calcitonin Gene\u2013Related Peptide\u2013Targeted Monoclonal Antibody Medications as Add-on Therapy to Onabotulinumtoxin A in Patients with Chronic Migraine","volume":"22","author":"Cohen","year":"2021","journal-title":"Pain Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1007\/s10072-021-05861-4","article-title":"Patient-reported outcomes of migraine treatment with erenumab: Results from a national patient survey","volume":"43","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dinh, B.B.K., Aziz, W.H., Terruzzi, A., and Krieger, D.W. (2021). Initial experience with novel CGRP-receptor inhibitor therapy in Migraine in the United Arab Emirates: A retrospective observational study. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02507-y"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","article-title":"Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: Results from a retrospective chart study","volume":"23","author":"Driessen","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40261-021-01059-w","article-title":"Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Qu\u00e9bec, Eastern Canada","volume":"41","author":"Eghtesadi","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40120-021-00245-4","article-title":"Real-World Treatment Profiles, Clinical Outcomes, and Healthcare Resource Utilization of Patients with Migraine Prescribed Erenumab: A Multicenter Chart-Review Study of US Headache Centers","volume":"10","author":"Faust","year":"2021","journal-title":"Neurol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/03331024211014616","article-title":"Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment\u2014A real-life cohort study","volume":"41","author":"Gantenbein","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/0333102420946725","article-title":"Real-world effectiveness and tolerability of erenumab: A retrospective cohort study","volume":"40","author":"Kanaan","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/ane.13599","article-title":"Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine","volume":"145","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Maraia, Z., Ricci, D., Rocchi, M.B.L., Moretti, A., Bufarini, C., Cavaliere, A., and Peverini, M. (2021). Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine\u2019s Prophylaxis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194425"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mechtler, L., Saikali, N., McVige, J., Hughes, O., Traut, A., and Adams, A.M. (2022). Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.788159"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"107200","DOI":"10.1016\/j.clineuro.2022.107200","article-title":"A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine","volume":"215","author":"Nandyala","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"774341","DOI":"10.3389\/fneur.2021.774341","article-title":"Gender Differences in 3-Month Outcomes of Erenumab Treatment\u2014Study on Efficacy and Safety of Treatment With Erenumab in Men","volume":"12","author":"Ornello","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-022-01408-w","article-title":"Comparing the relative and absolute effect of erenumab: Is a 50% response enough? Results from the ESTEEMen study","volume":"23","author":"Ornello","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ornello, R., Frattale, I., Caponnetto, V., De Matteis, E., Pistoia, F., and Sacco, S. (2021). Menstrual Headache in Women with Chronic Migraine Treated with Erenumab: An Observational Case Series. Brain Sci., 11.","DOI":"10.3390\/brainsci11030370"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and Onabotulinumtoxin A: A Dual-Center Retrospective Observational Study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000518899","article-title":"Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series","volume":"85","author":"Ruiz","year":"2022","journal-title":"Eur. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s10194-021-01323-6","article-title":"CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: A real-world experience","volume":"22","author":"Scheffler","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: First German real-world evidence","volume":"21","author":"Scheffler","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"846717","DOI":"10.3389\/fneur.2022.846717","article-title":"Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index","volume":"13","author":"Sette","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13760-021-01770-7","article-title":"Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: A two tertiary headache centers experience during clinical practice","volume":"122","author":"Storch","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1007\/s10072-021-05547-x","article-title":"Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxin A injections: Case series","volume":"42","author":"Toni","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jcpt.13620","article-title":"Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study","volume":"47","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10072-019-03839-x","article-title":"Erenumab: From scientific evidence to clinical practice\u2014The first Italian real-life data","volume":"40","author":"Barbanti","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/head.14194","article-title":"Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","article-title":"Fremanezumab in the prevention of high-frequency episodic and chronic migraine: A 12-week, multicenter, real-life, cohort study (the FRIEND study)","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/head.14291","article-title":"A real-world, observational study of erenumab for migraine prevention in Canadian patients","volume":"62","author":"Becker","year":"2022","journal-title":"Headache"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","article-title":"Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: Real-life effectiveness and predictors of response at 6 months","volume":"22","author":"Caronna","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/head.13968","article-title":"Erenumab in Chronic Migraine: An Australian Experience","volume":"60","author":"Cheng","year":"2020","journal-title":"Headache"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"De Luca, C., Baldacci, F., Mazzucchi, S., Lombardo, I., Curto, L., Ulivi, M., Chico, L., Papa, M., Siciliano, G., and Gori, S. (2021). CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194586"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s10072-020-05022-z","article-title":"Early outcomes of migraine after erenumab discontinuation: Data from a real-life setting","volume":"42","author":"Affaitati","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1111\/ene.15075","article-title":"Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study","volume":"28","author":"Lentsch","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","article-title":"Association between response to triptans and response to erenumab: Real-life data","volume":"22","author":"Frattale","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","article-title":"Chronic migraine evolution after 3 months from erenumab suspension: Real-world-evidence-life data","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/ene.15260","article-title":"Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine","volume":"29","author":"Iannone","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/03331024221076481","article-title":"Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients","volume":"42","author":"Kwon","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"107169","DOI":"10.1016\/j.clineuro.2022.107169","article-title":"Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience","volume":"214","author":"Cvetkovic","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","article-title":"Erenumab in 159 high frequency and chronic migraine patients: Real-life results from the Bologna Headache Center","volume":"41","author":"Matteo","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s10194-020-01171-w","article-title":"Conversion from chronic to episodic migraine in patients treated with erenumab: Real-life data from an Italian region","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","article-title":"Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache","volume":"43","author":"Pensato","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10072-020-04658-1","article-title":"Erenumab efficacy in highly resistant chronic migraine: A real-life study","volume":"41","author":"Pensato","year":"2020","journal-title":"Neurol. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10194-022-01417-9","article-title":"Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: A real-world experience","volume":"23","author":"Raffaelli","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain"},{"key":"ref_94","first-page":"557","article-title":"Immunotherapy for migraine: The use of erenumab in real life","volume":"221","author":"Ledesma","year":"2021","journal-title":"Rev. Clin. Esp."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"805334","DOI":"10.3389\/fneur.2021.805334","article-title":"Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes","volume":"12","author":"Schoenen","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment\u2014Real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","article-title":"The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: A real-world evidence observational study","volume":"268","author":"Gallardo","year":"2021","journal-title":"J. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"687697","DOI":"10.3389\/fneur.2021.687697","article-title":"Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus","volume":"12","author":"Tziakouri","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s10194-021-01247-1","article-title":"Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: A multicenter prospective cohort study (the GARLIT study)","volume":"22","author":"Vernieri","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/ene.15197","article-title":"Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study","volume":"29","author":"Vernieri","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s10194-021-01363-y","article-title":"Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: An observational longitudinal cohort study","volume":"22","author":"Vernieri","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/ene.15236","article-title":"Clinic and genetic predictors in response to erenumab","volume":"29","author":"Zecca","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","article-title":"Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: A pivotal study","volume":"43","author":"Cetta","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s10194-022-01480-2","article-title":"Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial","volume":"23","author":"Vaghi","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ene.15364","article-title":"Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence","volume":"29","author":"Khalil","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Alsaadi, T., Noori, S., Varakian, R., Youssef, S., and Almadani, A. (2022). Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. BMC Neurol., 22.","DOI":"10.1186\/s12883-022-02710-5"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: A 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s10194-022-01515-8","article-title":"Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): Interim results","volume":"23","author":"Gantenbein","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s10194-022-01426-8","article-title":"Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: A retrospective real-world study","volume":"23","author":"Schenk","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","article-title":"Two-year effectiveness of erenumab in resistant chronic migraine: A prospective real-world analysis","volume":"23","author":"Andreou","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","article-title":"Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine","volume":"23","author":"Driessen","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1007\/s00415-022-11226-4","article-title":"Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience","volume":"269","author":"Altamura","year":"2022","journal-title":"J. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","article-title":"Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: A real-world experience","volume":"23","author":"Silvestro","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/head.14400","article-title":"Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment","volume":"62","author":"Fofi","year":"2022","journal-title":"Headache"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ene.15563","article-title":"Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study","volume":"30","author":"Vernieri","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_116","first-page":"e1897","article-title":"Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study","volume":"99","author":"Lentsch","year":"2022","journal-title":"Neurology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","article-title":"Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine\u2014A Real-Life Study","volume":"13","author":"Nowaczewska","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1007\/s10072-022-06254-x","article-title":"Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine","volume":"43","author":"Quintana","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"973226","DOI":"10.3389\/fneur.2022.973226","article-title":"Cranial autonomic symptoms and response to monoclonal antibodies targeting the Calcitonin gene-related peptide pathway: A real-world study","volume":"13","author":"Caponnetto","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Cantarelli, L., Grafi\u00f1a, D.P., Perez, A.G., Gil, S.G., Nicol\u00e1s, F.G., Santana, E.R., D\u00e1vila, M.A.N., P\u00e9rez, S.M.O., G\u00f3mez, G.C., and Reyes, S.P. (2022). Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice. Ann. Pharmacother.","DOI":"10.1177\/10600280221118402"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s10194-022-01498-6","article-title":"Predictors of response to anti-CGRP monoclonal antibodies: A 24-week, multicenter, prospective study on 864 migraine patients","volume":"23","author":"Barbanti","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e2662","DOI":"10.1002\/brb3.2662","article-title":"Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies","volume":"12","author":"Nsaka","year":"2022","journal-title":"Brain Behav."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/03331024211037304","article-title":"Could erectile dysfunction be a side effect of CGRP inhibition? A case report","volume":"42","author":"MaassenVanDenBrink","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Albanese, M., and Mercuri, N.B. (2022). Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11051228"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104286","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.07.002","article-title":"Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report","volume":"28","author":"Aradi","year":"2019","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s42399-020-00369-y","article-title":"Treatment-Refractory Headache in the Setting of COVID-19 Pneumonia: Migraine or Meningoencephalitis? Case Report","volume":"2","author":"Arca","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Cullum, C.K., Olsen, M.K., Kocadag, H.B., Ashina, M., and Amin, F.M. (2021). Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: A case report. BMC Neurol., 21.","DOI":"10.1186\/s12883-021-02294-6"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/head.13596","article-title":"Raynaud\u2019s Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists","volume":"59","author":"Evans","year":"2019","journal-title":"Headache"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s10072-020-04931-3","article-title":"Erenumab during pregnancy: A case report in a patient with chronic migraine","volume":"42","author":"Fofi","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11739-020-02407-y","article-title":"Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab","volume":"16","author":"Frattale","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/03331024211017879","article-title":"Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases","volume":"41","author":"Madera","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10072-021-05329-5","article-title":"Impact of COVID-19 on chronic migraine treated with erenumab: A case report","volume":"42","author":"Grassini","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1089\/bfm.2019.0162","article-title":"Erenumab During Breastfeeding","volume":"14","author":"Henze","year":"2019","journal-title":"Breastfeed. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10072-021-05624-1","article-title":"Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: A prospective case series","volume":"43","author":"Iannone","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s11739-021-02787-9","article-title":"COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: A case report","volume":"16","author":"Iannone","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/head.13855","article-title":"De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm","volume":"60","author":"Kearney","year":"2020","journal-title":"Headache"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2021.01.015","article-title":"Galcanezumab-induced fixed drug eruption","volume":"9","author":"Klager","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0333102420950484","article-title":"Adverse effects of erenumab on cerebral proliferative angiopathy: A case report","volume":"41","author":"Lehman","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/03331024221075074","article-title":"Successful treatment of primary headache associated with sexual activity using erenumab: Case report","volume":"42","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1111\/head.13979","article-title":"Erenumab-Induced Severe Nausea Leading to Smoking Cessation: A Retrospective Case Series","volume":"60","author":"Mathew","year":"2020","journal-title":"Headache"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/cod.14018","article-title":"First confirmed case of nonimmediate hypersensitivity to fremanezumab during chronic migraine treatment","volume":"86","author":"Moya","year":"2022","journal-title":"Contact Dermat."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e2121","DOI":"10.1212\/WNL.0000000000008944","article-title":"Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy","volume":"94","author":"Mullin","year":"2020","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/head.13779","article-title":"Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis","volume":"60","author":"Ornello","year":"2020","journal-title":"Headache"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00210-022-02216-4","article-title":"Change in the second exteroceptive suppression period of the temporalis muscle during erenumab treatment","volume":"395","author":"Rota","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/03331024211037277","article-title":"Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention","volume":"42","author":"Rozen","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/jcpt.13595","article-title":"Two possible cases of erenumab-induced xerostomia","volume":"47","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"656294","DOI":"10.3389\/fneur.2021.656294","article-title":"Additive Interaction Between Onabotulinumtoxin-A and Erenumab in Patients With Refractory Migraine","volume":"12","author":"Silvestro","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/head.13832","article-title":"Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series","volume":"60","author":"Silvestro","year":"2020","journal-title":"Headache"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/head.14055","article-title":"Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report","volume":"61","author":"Spector","year":"2021","journal-title":"Headache"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.12788\/acp.0016","article-title":"Migraine and adult-onset stuttering: A proposed autoimmune phenomenon","volume":"33","author":"Wong","year":"2021","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/0333102420933571","article-title":"Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: A case report","volume":"40","author":"Wurthmann","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/head.13729","article-title":"Non-Responders to Treatment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class","volume":"60","author":"Ziegeler","year":"2020","journal-title":"Headache"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1007\/s10072-022-06391-3","article-title":"Preventive migraine treatment in mitochondrial diseases: A case report of erenumab efficacy and literature review","volume":"43","author":"Primiano","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40122-022-00417-6","article-title":"First Report of Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE or Baboon Syndrome) After Erenumab Application for Migraine Prevention","volume":"11","author":"Heinze","year":"2022","journal-title":"Pain Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/head.14393","article-title":"Gestational exposure to erenumab\u2014The outcome of three pregnancies","volume":"62","author":"Oliveira","year":"2022","journal-title":"Headache"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/phar.2706","article-title":"Myocardial infarction associated with erenumab: A case report","volume":"42","author":"Perino","year":"2022","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/head.14305","article-title":"The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review","volume":"62","author":"Vig","year":"2022","journal-title":"Headache"},{"key":"ref_158","first-page":"e30064","article-title":"Fremanezumab Improved Migraine and Headache Attributed to Glioblastoma","volume":"14","author":"Kawamura","year":"2022","journal-title":"Cureus"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"120462","DOI":"10.1016\/j.jns.2022.120462","article-title":"Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome?","volume":"443","author":"Suzuki","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/head.14372","article-title":"Nummular headache responsive to anti-calcitonin gene-related peptide monoclonal antibodies in a patient with migraine","volume":"62","author":"Cuadrado","year":"2022","journal-title":"Headache"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s10194-021-01330-7","article-title":"Inflammatory complications of CGRP monoclonal antibodies: A case series","volume":"22","author":"Ray","year":"2021","journal-title":"J. Headache Pain"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1007\/s00415-022-11128-5","article-title":"Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: A case report","volume":"269","author":"Cetta","year":"2022","journal-title":"J. Neurol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1111\/head.14208","article-title":"Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data","volume":"61","author":"Dodick","year":"2021","journal-title":"Headache"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/head.14051","article-title":"Hypertension: A new safety risk for patients treated with erenumab","volume":"61","author":"Saely","year":"2021","journal-title":"Headache"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","article-title":"Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: A real-world potential safety signal from the WHO pharmacovigilance database","volume":"23","author":"Merino","year":"2022","journal-title":"J. Headache Pain"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Silberstein, S.D., Reshef, S., Cohen, J.M., Gandhi, S., Seminerio, M., Ramirez Campos, V., Kessler, Y., Thompson, S.F., and Blumenfeld, A. (2022). Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System. Adv Ther.","DOI":"10.1007\/s12325-022-02346-4"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","article-title":"Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon","volume":"4","author":"Breen","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38, 1\u2013211.","DOI":"10.1177\/0333102417738202"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults","volume":"40","author":"Diener","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0333102419828967","article-title":"Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition","volume":"39","author":"Diener","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0333102420983292","article-title":"Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database","volume":"41","author":"Noseda","year":"2021","journal-title":"Cephalalgia"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1177\/0333102410362122","article-title":"Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries","volume":"30","author":"Edvinsson","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/sj.bjp.0707134","article-title":"Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery","volume":"150","author":"Edvinsson","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s10194-017-0811-5","article-title":"School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade\u2014Impact on the cranial vasculature","volume":"18","author":"Benemei","year":"2017","journal-title":"J. Headache Pain"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/143\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:55:28Z","timestamp":1760147728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/1\/143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":175,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["cells12010143"],"URL":"https:\/\/doi.org\/10.3390\/cells12010143","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}